Ness Tsiona-based Foamix, a developer of topical foam delivery systems for dermatology and other applications, said Monday it licensed its new lice treatment product PerFoam 1% to Taro Pharmaceutical Industries.
Foamix will transfer technology to Haifa-based Taro, which will upscale, manufacture, register and commercialize PerFoam 1% for distribution in Israel and the Palestinian territories. The companies did say what the deal was worth. The product is scheduled to be launched in late 2008.
Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>